A First-in-Human Phase I Study of Intravesical sEphB4-HSA in Patients With "BCG-Unresponsive" Bladder Carcinoma In Situ (CIS), Completely Resected High Grade Ta/T1, to Establish the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Status: Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; First in man
- 21 Oct 2019 Planned End Date changed from 1 Jul 2022 to 9 Dec 2022.
- 21 Oct 2019 Planned primary completion date changed from 1 Jul 2021 to 9 Dec 2021.
- 21 Oct 2019 Planned initiation date changed from 1 Jul 2019 to 9 Dec 2019.